You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiflorasone
Accession NumberDB00223  (APRD00921)
TypeSmall Molecule
GroupsApproved
DescriptionDiflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.
Structure
Thumb
Synonyms
(6alpha,11beta,16beta)-6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
(6α,11β,16β)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Diflorasona
Diflorasonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Florone Crm 0.05%cream.05 %topicalThe Upjohn Company Of Canada1980-12-311998-08-12Canada
Florone Ont 0.05%ointment.05 %topicalThe Upjohn Company Of Canada1980-12-311998-08-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apexiconointment.5 mg/gtopicalPharmaDerm, A division of Nycomed US Inc.2009-09-30Not applicableUs
Apexicon Ecream.5 mg/gtopicalPharma Derm, A Division Of Nycomed Us Inc.2009-09-302016-03-11Us
Apexicon Ecream.5 mg/gtopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.2002-12-20Not applicableUs
Diflorasone Diacetatecream.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2000-04-24Not applicableUs
Diflorasone Diacetatecream.5 mg/gtopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1998-03-30Not applicableUs
Diflorasone Diacetateointment.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1999-04-27Not applicableUs
Diflorasone Diacetateointment.5 mg/gtopicalVersa Pharm Incorporated2016-03-08Not applicableUs
Diflorasone Diacetatecream.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-12-20Not applicableUs
Diflorasone Diacetateointment.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1999-05-14Not applicableUs
Psorconcream5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FloroneGalderma
Florone ENot Available
MaxiflorNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Diflorasone diacetate
ThumbNot applicableDBSALT000887
Categories
UNIIT2DHJ9645W
CAS number2557-49-5
WeightAverage: 410.4515
Monoisotopic: 410.190480416
Chemical FormulaC22H28F2O5
InChI KeyInChIKey=WXURHACBFYSXBI-XHIJKXOTSA-N
InChI
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,13S,14R,15S,17S)-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[[email protected]](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
PharmacodynamicsLike other topical corticosteroids, diflorasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Diflorasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mechanism of actionThe precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Related Articles
AbsorptionTopical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingBound to plasma proteins in varying degrees.
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityTopically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.971
Caco-2 permeable+0.747
P-glycoprotein substrateSubstrate0.7725
P-glycoprotein inhibitor INon-inhibitor0.7629
P-glycoprotein inhibitor IINon-inhibitor0.9002
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.8789
CYP450 2D6 substrateNon-substrate0.9031
CYP450 3A4 substrateSubstrate0.6991
CYP450 1A2 substrateNon-inhibitor0.9313
CYP450 2C9 inhibitorNon-inhibitor0.9254
CYP450 2D6 inhibitorNon-inhibitor0.939
CYP450 2C19 inhibitorNon-inhibitor0.9234
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8979
Ames testNon AMES toxic0.8509
CarcinogenicityNon-carcinogens0.9232
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3293 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.6022
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Altana inc
  • Taro pharmaceuticals usa inc
  • Pharmacia and upjohn co
  • Sanofi aventis us llc
  • Taro pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Creamtopical.5 mg/g
Ointmenttopical.5 mg/g
Creamtopical.05 %
Ointmenttopical.05 %
Creamtopical5 mg/g
Prices
Unit descriptionCostUnit
Psorcon 0.05% Ointment 60 gm Tube145.75USD tube
Psorcon 0.05% Cream 60 gm Tube137.58USD tube
Diflorasone Diacetate 0.05% Cream 60 gm Tube101.11USD tube
Diflorasone Diacetate 0.05% Ointment 60 gm Tube100.5USD tube
Diflorasone Diacetate 0.05% Cream 30 gm Tube52.81USD tube
Diflorasone Diacetate 0.05% Ointment 30 gm Tube52.29USD tube
Diflorasone Diacetate 0.05% Cream 15 gm Tube38.25USD tube
Diflorasone Diacetate 0.05% Ointment 15 gm Tube38.05USD tube
Psorcon 0.05% cream3.45USD g
Diflorasone 0.05% cream1.5USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0853 mg/mLALOGPS
logP1.91ALOGPS
logP1.34ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.32 m3·mol-1ChemAxon
Polarizability40.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Lincoln, F.H., Schneider, W.P. and Spero, G.B.; U.S. Patent 3,557,158; January 19,1971; assigned to The Upjohn Company.
Ayer, D.E., Schiagel, C.A. and Flynn,G.L.; US. Patent 3,980,778; September 14,1976; assigned to The Upjohn Co.

General ReferencesNot Available
External Links
ATC CodesD07AC10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (26.8 KB)
MSDSDownload (81.9 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Diflorasone is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diflorasone.
AldesleukinDiflorasone may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Diflorasone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Diflorasone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Diflorasone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Diflorasone.
AmiodaroneThe serum concentration of Diflorasone can be increased when it is combined with Amiodarone.
Amphotericin BDiflorasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Diflorasone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Diflorasone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Diflorasone.
BazedoxifeneThe serum concentration of Diflorasone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideDiflorasone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Diflorasone.
Bismuth SubcitrateThe bioavailability of Diflorasone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Diflorasone can be increased when it is combined with Boceprevir.
BumetanideDiflorasone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Diflorasone.
Calcium carbonateThe bioavailability of Diflorasone can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Diflorasone can be decreased when it is combined with Carbamazepine.
CeritinibDiflorasone may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Diflorasone can be increased when it is combined with Ceritinib.
ChlorothiazideDiflorasone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Diflorasone can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneDiflorasone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Diflorasone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Diflorasone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Diflorasone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Diflorasone.
CoumaphosThe risk or severity of adverse effects can be increased when Diflorasone is combined with Coumaphos.
DarunavirThe serum concentration of Diflorasone can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Diflorasone is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Diflorasone is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Diflorasone is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Diflorasone is combined with Dichlorvos.
DienestrolThe serum concentration of Diflorasone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Diflorasone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diflorasone.
DihydrotestosteroneDiflorasone may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Diflorasone is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Diflorasone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Diflorasone is combined with Edrophonium.
EnzalutamideThe serum concentration of Diflorasone can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Diflorasone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Diflorasone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Diflorasone can be increased when it is combined with Estrone.
Etacrynic acidDiflorasone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Diflorasone can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Diflorasone is combined with Fenthion.
FluoxymesteroneDiflorasone may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Diflorasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Diflorasone can be decreased when it is combined with Fosphenytoin.
FurosemideDiflorasone may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Diflorasone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Diflorasone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Diflorasone is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Diflorasone.
HexestrolThe serum concentration of Diflorasone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Diflorasone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflorasone.
HydrochlorothiazideDiflorasone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideDiflorasone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Diflorasone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Diflorasone.
IndapamideDiflorasone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Diflorasone can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Diflorasone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Diflorasone.
ItraconazoleThe serum concentration of Diflorasone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Diflorasone can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Diflorasone can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Diflorasone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Diflorasone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Diflorasone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Diflorasone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Diflorasone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Diflorasone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diflorasone.
MestranolThe serum concentration of Diflorasone can be increased when it is combined with Mestranol.
MethyclothiazideDiflorasone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneDiflorasone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneDiflorasone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Diflorasone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Minaprine.
MitotaneThe serum concentration of Diflorasone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Diflorasone.
NefazodoneThe serum concentration of Diflorasone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Diflorasone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Neostigmine.
NevirapineThe serum concentration of Diflorasone can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Diflorasone is combined with Nicorandil.
OxandroloneDiflorasone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneDiflorasone may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Diflorasone can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Diflorasone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Diflorasone.
PhenytoinThe serum concentration of Diflorasone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Physostigmine.
PiretanideDiflorasone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Diflorasone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideDiflorasone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Diflorasone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Diflorasone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Diflorasone can be increased when it is combined with Quinestrol.
QuinethazoneDiflorasone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Diflorasone.
RifabutinThe serum concentration of Diflorasone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Diflorasone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Diflorasone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Diflorasone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Diflorasone.
SaquinavirThe serum concentration of Diflorasone can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Diflorasone.
StanozololDiflorasone may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Diflorasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Diflorasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Diflorasone.
TelaprevirThe serum concentration of Diflorasone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Diflorasone can be increased when it is combined with Telithromycin.
TestosteroneDiflorasone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Diflorasone can be increased when it is combined with Tibolone.
TorasemideDiflorasone may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Diflorasone is combined with Trichlorfon.
TrichlormethiazideDiflorasone may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Diflorasone is combined with Tubocurarine.
VoriconazoleThe serum concentration of Diflorasone can be increased when it is combined with Voriconazole.
WarfarinDiflorasone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Diflorasone can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR: Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004 Jul;15(4):235-8. [PubMed:15764038 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23